Spark Therapeutics Inc (NASDAQ:ONCE) – Equities researchers at Wedbush boosted their Q4 2017 earnings per share (EPS) estimates for Spark Therapeutics in a research note issued on Tuesday. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will post earnings of ($1.58) per share for the quarter, up from their prior estimate of ($1.71). Wedbush has a “Neutral” rating and a $50.00 price objective on the stock. Wedbush also issued estimates for Spark Therapeutics’ Q1 2018 earnings at ($1.80) EPS, Q2 2018 earnings at ($1.76) EPS, Q3 2018 earnings at ($1.74) EPS, Q4 2018 earnings at ($1.69) EPS, FY2018 earnings at ($6.99) EPS, FY2019 earnings at ($5.32) EPS, FY2020 earnings at ($2.77) EPS and FY2021 earnings at $0.73 EPS.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.07) earnings per share.

Several other equities analysts also recently commented on the stock. ValuEngine downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. BMO Capital Markets reiterated a “buy” rating and set a $101.00 price target on shares of Spark Therapeutics in a report on Wednesday, November 15th. Cantor Fitzgerald reiterated a “buy” rating and set a $105.00 price target (up from $94.00) on shares of Spark Therapeutics in a report on Tuesday, October 10th. Goldman Sachs Group reiterated a “buy” rating and set a $111.00 price target on shares of Spark Therapeutics in a report on Friday, October 6th. Finally, Barclays upped their price target on shares of Spark Therapeutics from $104.00 to $107.00 and gave the company an “overweight” rating in a report on Friday, October 13th. Two analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $76.19.

Spark Therapeutics (NASDAQ ONCE) opened at $45.21 on Friday. Spark Therapeutics has a fifty-two week low of $41.06 and a fifty-two week high of $91.75.

A number of hedge funds have recently modified their holdings of the business. Cornerstone Capital Management Holdings LLC. lifted its position in shares of Spark Therapeutics by 3.2% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 11,089 shares of the biotechnology company’s stock worth $662,000 after purchasing an additional 342 shares during the period. Ameritas Investment Partners Inc. lifted its position in shares of Spark Therapeutics by 23.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 389 shares during the period. Teachers Advisors LLC lifted its position in shares of Spark Therapeutics by 1.9% in the 1st quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock worth $1,842,000 after purchasing an additional 650 shares during the period. California Public Employees Retirement System lifted its position in shares of Spark Therapeutics by 2.1% in the 2nd quarter. California Public Employees Retirement System now owns 39,100 shares of the biotechnology company’s stock worth $2,336,000 after purchasing an additional 800 shares during the period. Finally, Great West Life Assurance Co. Can lifted its position in shares of Spark Therapeutics by 47.3% in the 3rd quarter. Great West Life Assurance Co. Can now owns 3,939 shares of the biotechnology company’s stock worth $351,000 after purchasing an additional 1,264 shares during the period. Institutional investors and hedge funds own 94.94% of the company’s stock.

In other Spark Therapeutics news, CFO Stephen W. Webster sold 10,000 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $70.14, for a total value of $701,400.00. Following the transaction, the chief financial officer now directly owns 12,500 shares in the company, valued at approximately $876,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Katherine A. High sold 5,000 shares of the company’s stock in a transaction dated Tuesday, September 26th. The stock was sold at an average price of $86.16, for a total transaction of $430,800.00. Following the completion of the transaction, the insider now owns 215,000 shares in the company, valued at $18,524,400. The disclosure for this sale can be found here. Insiders sold a total of 1,068,809 shares of company stock worth $89,809,385 over the last 90 days. Insiders own 7.30% of the company’s stock.

WARNING: This article was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.dailypolitical.com/2017/12/15/wedbush-comments-on-spark-therapeutics-incs-q4-2017-earnings-once.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.